Recently, the Wall Street Journal published an interesting article expressing the argument that our healthcare system would be “less burdened” if coronavirus patients were treated prior to requiring hospitalization and suggesting that their are therapeutic options that patients can take themselves at in the comfort of their respective houses. The article is titled “Too Much Caution Is Killing Covid Patients -Doctors should follow the evidence for promising therapies. Instead they demand certainty.“
One interesting excerpt from the article read as follows: “Too many doctors have interpreted the term “evidence-based medicine” to mean that the evidence for a treatment must be certain and definitive before it can be given to patients. Because accusing a physician of not being “evidence based” can be a career-damaging allegation, fear of straying from the pack has prevailed, favoring inertia and inaction amid uncertainty about Covid-19 treatments.”
This topic is also the subject of a Nov. 19 hearing before the Senate Homeland Security and Governmental Affairs Committee. You can check out their article/video titled: “Early Outpatient Treatment: An Essential Part of a COVID-19 Solution”
Currently, Seattle-based Atossa Therapeutics (NASDAQ: ATOS) is working on AT-301 which is their proprietary COVID-19 nasal spray program that is being developed for at home use for patients recently diagnosed with COVID-19. There are currently no FDA-approved therapies to treat COVID-19 at home.
You may learn more at Atossa’s website : www.atossathereapeutics.com